Carcinoid Tumor Metastases to the Extraocular Muscles: MR Imaging and CT Findings and Review of the Literature

A. Gupta, J.L. Chazen and C.D. Phillips

AJNR Am J Neuroradiol 2011, 32 (7) 1208-1211
doi: https://doi.org/10.3174/ajnr.A2470
http://www.ajnr.org/content/32/7/1208
Carcinoid tumors are rare neuroendocrine neoplasms derived from enterochromaffin cells, which are found primarily in the gastrointestinal tract and bronchial tree.\(^1,2\) Liver metastases are the classic presentation of distant disease, which can lead to carcinoid syndrome (flushing, diarrhea, and wheezing) and right-sided valvar heart disease. However as treatment options improve and survival increases, new metastatic patterns have been increasing in frequency.\(^3\) Although rare, metastatic carcinoid to the extraocular muscles has been relatively well described in both retrospective case reports and clinical series in the ophthalmology literature.\(^4,8,15\) We present the first series detailing the CT and MR imaging findings of carcinoid tumor metastases to the EOMs.

**Materials and Methods**

A waiver of informed consent was obtained from our institutional review board, and in a manner consistent with Health Insurance Portability and Accountability Act regulations, we retrospectively collected clinical data and CT and MR images available from our institution in patients with known carcinoid tumor. In addition, via a survey of head and neck radiologists from collaborating institutions, additional cases were collected. All imaging analyzed for this study was performed from January 2000 through October of 2010.

We found a total of 7 patients with known metastatic disease to the EOMs. The primary inclusion criterion was the presence of EOM lesions in patients with known metastatic carcinoid tumor, though the presence of non-EOM intraorbital disease was not considered an exclusion criterion. Patients were not included in this study if any alternate diagnosis such as an infectious or inflammatory condition of the EOM could not be excluded on the basis of the amalgam of clinical and imaging data available in the medical record or as directly provided to the radiologist by the referring physician. A clinical chart review was performed to collect patient age, sex, symptoms, site of original tumor, and means of diagnosis. Specific clinical symptoms at the time of the imaging were available for 5 of the 7 patients in the series.

We retrospectively reviewed the MR imaging (\(n = 5\)) or CT (\(n = 2\)) examinations for these patients. In all patients, contrast-enhanced orbital imaging was available for review. For all CT examinations, postcontrast imaging was performed after the administration of non-ionic contrast material. Coronal reconstructions were available in all patients with CT examinations. All MR imaging sequences were performed with 1.5T or higher scanners, with, at the minimum, pre- and postgadolinium-enhanced T1-weighted images available for review.

All images were directly reviewed by a neuroradiology fellow, a senior radiology resident, and a head and neck radiologist with a Certificate of Added Qualification in Neuroradiology and >20 years of experience. We evaluated imaging findings including the following: 1) the distribution of EOMs involved (including the presence or absence of bilateral lesions), 2) the lesion morphology (fusiform, round, or irregular), 3) the margin of the lesion (well-circumscribed or infiltrative and involving adjacent structures), 4) involvement of the tendinous insertion of the muscle onto the globe, and 5) the attenuation or intensity of the lesion on postcontrast imaging relative to uninvolved EOM. We also reviewed for the presence or absence of other (non-EOM) orbital metastatic disease.

**Results**

**Summary of Patient Data**

The imaging and clinical findings are summarized in the Table. Figures 1–4 show representative cases. Six of 7 patients were women, and the mean age was 61.9 years. All lesions...
A total of 17 separate muscle insertions were evaluated were well-defined, round or fusiform, without involvement of adjacent intraorbital structures, tendinous insertion of the globe, or osseous structures of the orbit. In the 5 patients with MR imaging, postgadolinium T1-weighted imaging findings by an alternative diagnosis, and responded clinically in a manner consistent with metastatic neuroendocrine tumor (eg, sensitivity to appropriate radiotarget therapy or chemotherapy). An illustrative case history is provided below:

**Case History: Patient 1**

This 64-year-old woman presented in late 2005 with abdominal pain. CT of the chest, abdomen, and pelvis revealed multiple liver lesions, hilar adenopathy, and diffuse sclerotic osseous lesions. Laboratory values revealed elevated serotonin levels. An indium-111 octreotide scan revealed multifocal lesions involving the liver, the lung hilum, and osseous structures. Sonographically guided biopsy of the liver lesion revealed metastatic well-differentiated carcinoid tumor, with the primary site unknown. The patient was treated with multiple rounds of chemotherapy with a waxing and waning response. In June 2007, the patient developed biopsy-proved metastatic neck lymphadenopathy from the carcinoid primary and still had evidence of extensive abdominal metastatic disease.

In December 2009, the patient presented with a left CN VI palsy but was otherwise asymptomatic from a neurologic perspective. MR imaging of the brain in December 2009 revealed multiple lesions involving the liver, the lung hilum, and osseous structures. Given the absence of a competing diagnostic consideration, the decision was made to proceed with therapy without radionuclide scintigraphy or direct EOM biopsy. The patient was treated with neoadjuvant chemotheraphy followed by external beam radiation therapy to the EOM with evidence of positive treatment response on follow-up MR imaging in February 2010.

Pathology samples (available in 3 patients) revealed carcinoid tumors that originated from an unknown site after a liver biopsy (patients 1 and 7) and from the pancreas after biopsy of a liver lesion (patient 5). In the remaining 4 cases, the patients had a known history of metastatic carcinoid tumor and had developed orbital lesions that could not reasonably be explained both clinically and on the basis of imaging findings by an alternative diagnosis, and responded clinically in a manner consistent with metastatic neuroendocrine tumor (eg, sensitivity to appropriate radiotarget therapy or chemotherapy). An illustrative case history is provided below:

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Clinical Presentation</th>
<th>CT or MRI Available</th>
<th>EOMs Involved</th>
<th>Lesion Morphology</th>
<th>Lesion Margins</th>
<th>Involvement of Insertion of EOM on Globe</th>
<th>Postcontrast Relative to Normal EOM</th>
<th>Density/Intensity on Postcontrast Relative to Normal EOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>64</td>
<td>F</td>
<td>Proptosis and CN VI palsy</td>
<td>MRI</td>
<td>Rt. MR</td>
<td>Fusiform</td>
<td>Well-defined</td>
<td>No</td>
<td>Mildly hyperintense</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>42</td>
<td>F</td>
<td>Gaze difficulty and tearing</td>
<td>CT</td>
<td>Lt. LR</td>
<td>Fusiform</td>
<td>Well-defined</td>
<td>No</td>
<td>Moderately hyperdense</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>71</td>
<td>F</td>
<td>N/A</td>
<td>MRI</td>
<td>Rt. SO</td>
<td>Round</td>
<td>Well-defined</td>
<td>No</td>
<td>Mildly hypointense</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>71</td>
<td>F</td>
<td>N/A</td>
<td>MRI</td>
<td>Rt. LR, SO, MR, SO, Lt. LR and IR</td>
<td>Round and fusiform</td>
<td>Well-defined</td>
<td>No</td>
<td>Mildly hypointense</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>62</td>
<td>F</td>
<td>Proptosis and pain</td>
<td>MRI</td>
<td>Rt. LR, MR</td>
<td>Round and fusiform</td>
<td>Well-defined</td>
<td>No</td>
<td>Mildly hyperdense</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>53</td>
<td>F</td>
<td>Proptosis and gaze difficulty</td>
<td>CT</td>
<td>Lt. LR, SR, MR</td>
<td>Round and fusiform</td>
<td>Well-defined</td>
<td>No</td>
<td>Mildly hyperdense</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>70</td>
<td>M</td>
<td>Blurry vision</td>
<td>MRI</td>
<td>Lt. LR, IR, Lt. IO</td>
<td>Fusiform</td>
<td>Well-defined</td>
<td>No</td>
<td>Isointense</td>
<td></td>
</tr>
</tbody>
</table>
of the right lateral (arrow) and left inferior recti (arrowhead). Man et al,14 of a single metastatic lesion to the orbit has been reported in the ophthalmology literature, only a single case report from 1987 by Braffman et al,4,6,8,11,17 In the English radiology literature, fewer than 40 cases have been reported in the ophthalmology literature, suggests a tendency for both intraorbital, extramuscular, and EOM metastatic disease in patients with carcinoid tumor.1 Metastases to the orbit do occur, generally in advanced disease, and are estimated to represent a disproportionately high percentage of all orbital metastases—approximately 5%.16 Despite this, to our knowledge, fewer than 40 cases have been reported in the ophthalmology/surgical literature.4,6,8,11,13,17 In the English radiology literature, only a single case report from 1987 by Braffman et al,14 of a single metastatic lesion to the orbit has been described. Our series demonstrates that these lesions can appear as well-circumscribed, fusiform, or round masses within the EOM muscle belly. In addition, although carcinoid metastases elsewhere in the body are typically thought of as hypervascular lesions, marked or avid postgadolinium enhancement was not a uniformly identified feature of these lesions in our series. The lesions were generally mildly hypointense on T2-weighted imaging and mildly hyperattenuating to uninvolved EOM on contrast-enhanced CT.

EOM metastases are well-described in a host of primary neoplasms, including breast, prostate, kidney, lung, and melanoma.5,15,18,19 Our experience, combined with the existing ophthalmology literature, suggests a tendency for both intraorbital, extramuscular, and EOM metastatic disease in patients with carcinoid primary tumors.4,6,8,11,13,17 Reports suggest that uveal tract carcinoid metastases are more commonly noted in bronchial lesions, whereas EOM metastases more commonly occur in gastrointestinal primary carcinoids.7,8,13 Although our sample size was small and pathology was incomplete, our series is consistent with this distribution as gastrointestinal tract disease with liver metastases was demonstrated in those patients with available corroborating clinical data. The pathophysiology for carcinoid (or other neoplasms) to seed the EOMs versus other components of the orbit is unknown, though some authors speculate, and it seems likely, that an immunologic mechanism or tumor cell adhesion factors in the local cellular microenvironment may play a role.5,20

Regarding bilateral and multifocal disease, a study by Mehta et al13 of 13 patients with orbital carcinoid metastases showed that only 2 of 13 patients had bilateral lesions and no quadrant was favored. In contrast, our limited series showed a relatively higher proportion of bilaterality (5 of 7 patients) and a slight predominance of lesions in the lateral rectus. Also, 6 of our 7 patients were women, which is of interest in light of the known slight predominance of carcinoid tumor in women (55%),1 and the mild female bias noted in prior literature reviews for orbital metastases.13 However, given the small sample size of this and other series, the significance of such numeric comparisons is somewhat limited.

However, knowledge of the propensity of carcinoid tumors to spread to the EOM in patients with metastatic disease is of greater importance. MR imaging or CT remain excellent tools to evaluate the presence of these lesions, with focal nodular enlargement of the muscle without invasion of the orbital fat or adjacent osseous structures highly suggestive of EOM metastases in a patient with known malignancy.3 Furthermore, cross-sectional imaging can demonstrate bilateral disease even if only unilateral symptoms are present. Although other entities such as thyroid orbitopathy, infectious myositis, or idopathic orbital inflammatory syndrome may produce a similar appearance,20 in the context of a known primary carcinoid, a metastasis should be high in the radiologic differential. Historically, confirmation of the diagnosis via tissue sampling, radionuclide scintigraphy with a somatostatin analog or I-131 meta-iodobenzylguanidine, or the appropriate combination of cross-sectional imaging findings and clinical history would result in orbital exenteration.8,13 However, with advances in chemotherapy and radiation treatment protocols, early or limited disease may not require radical surgical resection. Given the limited role of physical or ophthalmologic examination findings in confidently diagnosing EOM metastases, imaging may be the primary means of detecting this entity. As a consequence, suggestion of this entity by the radiologist may play an important role in the care of these patients.
Acknowledgments
We thank Wendy R. Smoker, MD, Laurie Loevner, MD, Deborah Shatzkes, MD, and A. John Tsiouris, MD, for their kind assistance in helping to identify potential cases for our series.

References